Overview
This study evaluates the safety and effectiveness of romosozumab injection compared to usual care for children and adolescents with Osteogenesis Imperfecta (OI) Types I, III, or IV. The study involves three parts: screening, treatment period, and safety follow-up over about 15 months.
